“Drug Costs”

15 result(s)
Drug Pipeline
After many years of failure, there is hope for potential treatments that could slow disease progression for those with Alzheimer's Disease. If approved, Biogen's... More
Feature
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature
Drug Pipeline
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization... More
Feature
Cost Management
Payors are projected to save on per-member-per-month costs from strategic formulary removals designed to help mitigate the effect of high-cost and hyperinflationary drugs More
Briefing
Cost Management
New GAO report shows that rebates negotiated on behalf of payors may help control premiums and provides further proof of the value PBMs bring to payors and members. More
Commentary
Twisting mountain road in the Swiss alps
Public Policy
Proposed HHS rule would eliminate rebates PBMs negotiate for Part D plans and MCOs, and may eventually affect all plans. Manufacturers would retain 15% of rebates currently... More
Briefing
Origami boats
Cost Management
The Guaranteed Net Cost model guarantees average net spend per prescription, after discounts and rebates, for each distribution channel. More
Feature
Sitting man holding two pills and a glass of water
Cost Management
CVS Health responded to the Administration's Blueprint on lowering drug costs and highlighted what the company does to control costs. We also recommended things the... More
Commentary
Icon of pharmacist filling prescriptions in a timely manner
Cost Management
Paying-for-performance is where health care is headed. CVS Health’s new performance network will deliver unit cost savings, as well as improved clinical outcomes to help lower... More
Briefing
Lady suffering from migraine, pressing hand against forehead
Drug Pipeline
The market for migraine medications is ripe for growth due to a large patient population with an unmet clinical need. Four investigational medications known CGRP inhibitors will... More
Feature